generated by gene targeting: these mutant mice developed pulmonary disease characteristic of PAP. In these animal models haematopoietic development and function were not Pulmonary alveolar proteinosis (PAP) is a disease of unknown etiopathogenesis sometimes associated with disturbed. [4][5][6] When found in association with haematological dismalignant haematological disorders. The potential reversibility of the process in these cases seems to be orders, PAP has been considered a secondary form. 7 In a series of haematology patients with respiratory failure, the related to recovery from the underlying disease. GM-CSF has acquired an important, potentially pathogenic incidence of PAP was 5.3%. 8 It has been suggested that in such cases, PAP may be the result of a disease-related role and BMT presents one therapeutic option effective in certain forms of human PAP. We present the case of defect in the AM function 9 and/or due to treatment (chemotherapy, radiotherapy, steroids). 10 The most signifia 43-year-old female patient with Ph؉ CML. During pretransplantation evaluation, unexpected pulmonary cant complication in both primary and secondary cases is superinfection, particularly by opportunistic organisms. The infiltrates were noted in the chest X-ray, PAP being diagnosed on biopsy. In view of the progressive respirpreferred diagnostic method both in primary 11 and secondary 8 PAP is bronchoalveolar lavage (BAL). atory symptomatology and her CML being in accelerated phase, the patient underwent haematopoietic transSpontaneous remission of idiopathic primary PAP has occasionally been described. 12 The use of BAL as therapy plantation. She died on day ؉12 from invasive pulmonary aspergillosis before a response could be has improved the prognosis considerably. However, the potential reversibility of the process in secondary PAP is observed. Pathogenic implications in PAP and the role of haematopoietic transplantation in this disease are related to prior recovery from the haematological condition. 8 The possible part played by a deficiency of GMdiscussed. Keywords: pulmonary alveolar proteinosis; CML; PBSC CSF in the pathogenesis of human PAP opens up new therapeutic possibilities, such as BMT 13 or treatment with transplantation; aspergillosis GM-CSF. 14 We present a case of PAP diagnosed in a female with CML. The patient underwent allogeneic haematopoietic Pulmonary alveolar proteinosis (PAP) is a heterogenous transplantation with the objective of achieving recovery and group of congenital and acquired diseases. It is characsubsequent control of the respiratory symptomatology. terized by deposition of extracellular granular material consisting of a mixture of phospholipids and surfactant proteins within the alveoli and airways. In humans, a fatal form of Case report congenital PAP arises from a mutation resulting in surfactant protein-B (SP-B) deficiency.
We present a case of PAP diagnosed in a female with CML. The patient underwent allogeneic haematopoietic Pulmonary alveolar proteinosis (PAP) is a heterogenous transplantation with the objective of achieving recovery and group of congenital and acquired diseases. It is characsubsequent control of the respiratory symptomatology. terized by deposition of extracellular granular material consisting of a mixture of phospholipids and surfactant proteins within the alveoli and airways. In humans, a fatal form of Case report congenital PAP arises from a mutation resulting in surfactant protein-B (SP-B) deficiency.
1 Acquired forms may be A 43-year-old female was diagnosed with CML Phϩ in found in previously healthy patients, but the pathogenic chronic phase during hospitalization due to left lower lobe mechanism is unclear. It may result from an imbalance in pneumonia. Radiographic images at the time of diagnosis the catabolism and clearance of alveolar phospholipids, secdid not reveal any other pathologies. Treatment with hydondary to either an impairment of alveolar macrophage roxyurea 1 g/day was begun. (AM) function 2 or excessive type II pneumocyte surfacAt pretransplantation evaluation, 7 months after diagtant production. 3 nosis, the patient was eupneic although there was poor air The critical role of GM-CSF in pulmonary homeostasis entry during pulmonary auscultation. The haemogram has been revealed by different studies with GM-CSFshowed a leukocytosis of 32 ϫ 10 9 /l with 89% neutrophils deficient mice or GM-CSF/IL3/5␤c receptor/deficient mice, and no blasts, Hb 10.8 g/dl and platelet count 944 ϫ 10 9 /l. A bone marrow aspirate-biopsy showed myeloid blasts (6% nucleated cells), and so accelerated CML was diagnosed. In positive, revealing the Ph chromosome and bcr/abl rearrangement. Chest X-ray showed a bilateral alveolar picture, it was decided to perform allogeneic haematopoietic transplantation with PBSC. Conditioning was with infiltrate with hila of increased size due to adenopathy (Figure 1 ), which was confirmed on CT scan. The findings busulfan and cyclophosphamide. 15 GVHD prophylaxis was with cyclosporin A and methotrexate. From day ϩ1 G-CSF in spirometry corresponded to a ventilatory capacity within the lower normal range with a trend towards restriction was administered at 5 g/kg/day subcutaneously. Fever started on day ϩ4, and progressive respiratory dif-(FVC = 79%, FEV 1 = 77%). Diffusing capacity of the lung for carbon monoxide (DL CO ) test showed normal gas transficulties worsened over the following days with an increase in the bilateral pulmonary infiltrates on X-ray. Broad-specfer capacity (TLCOcSB = 95%, TLCOc/VA = 84%). Pulmonary biopsy, performed by thoracotomy, revealed the trum antibiotic therapy was started with amphotericin B, ganciclovir and Igs at high doses. Blood cultures for bacpresence of PAS-positive intra-alveolar eosinophilic material. Both direct observation and culture of bronchial teria, fungi and viruses were negative. No improvement was noted in the patient, who required oxygen therapy; the aspirate were negative for fungi, and no hypha were found.
In view of the good performance of the patient, who had fever persisted until her death, which occurred as a result of respiratory distress on day ϩ12. Granulocytic and platelet no respiratory symptomatology, treatment with hydroxyurea was maintained with the objective of resolving the proengraftment was achieved on day ϩ11. Post-mortem pulmonary examination confirmed the diagteinosis, which was assumed to be related to the underlying leukaemic process.
nosis of PAP (Figure 2 ). Invasive pulmonary aspergillosis and pulmonary infarctions were also found. Bone marrow In subsequent evaluations, and in spite of haematological control of CML being achieved, no significant radiographic findings showed normal myelopoiesis and no signs of CML. Molecular studies were not performed. changes were noted in the pulmonary infiltrates. Progressive clinical respiratory impairment occurred, developing 4 months later into moderate exercise dyspnea and acropachy, with a worsening of functional tests and decreased gas Discussion transfer capacity (FVC = 80%, FEV 1 = 82%, TCLOcSB = 53%, TCLOc/VA = 62%).
Secondary PAP is a clinical entity that sometimes develops alongside other diseases. In the case of haematological neoDue to the accelerated phase of the haematological condition, and in view of the progressive clinical respiratory plasias, PAP usually occurs during the phase of postchemotherapy neutropenia 8 or in the chronic stage of the condition when the patients have received multiple treatments. 10 Busulfan is known to cause an entity known as 'busulfan lung', which occurs after long-term administration of this agent. 16 It is thought that busulfan may also contribute to PAP. 17 In our patient, PAP manifested soon after diagnosis, and the patient had not received large doses of chemotherapy or busulfan prior to transplantation. Neutropenia was not present at any time.
Experiments with mouse models are currently suggesting that GM-CSF plays a leading role in pulmonary homeostasis. Specifically, deficiency of GM-CSF, or of its receptor, may be a fundamental causative factor behind PAP. 5, 6 However, the sites of expression and the regulatory role played by GM-CSF in normal lung physiology have not been identified. GM-CSF seems to act locally, rather than peripherally, to correct the alveolar proteinosis in GM-CSF deficient mice (GMϪ/Ϫ mice). Nevertheless, it remains possible that it acts during granulo-monocytoid maturation in other organs to correct proteinosis. 6 It is unclear whether abnormalities of surfactant homeostasis seen in GMϪ/Ϫ mice are mediated by interactions of GM-CSF with alveolar macrophages, type II epithelial cells, or both. Either type II cells or macrophages participate in surfactant catabolism. 18 Recent findings demonstrate that type II and other respiratory epithelial cells are capable of synthesizing GM-CSF. 19 The fact that regression of this process has been achieved in GMϪ/Ϫ mice using BMT suggests that this disorder may be haematopoietic in nature, involving AM. In the aforementioned animal model, the donor origin of AM was demonstrated. 6 The role of BMT in human PAP is as yet undefined, but preliminary observations of abnormal AM have also been made in the human PAP. 19 Dirksen et al have recently described a subset of paediatric PAP patients, ery of AM and polymorphonuclear cells, which are quantitatively reduced during neutropenia. 21 Dirksen et al 13 protwo of whom had AML, with a striking reduction or absence of ␤c protein expression on the cell surface.
poses that elimination of the malignant clone by myeloablative therapy and unrelated haematopoietic stem Reduced function, or absence of ␤c was demonstrated in all patients. The role of GM-CSF in PAP complicating CML cell transplantation leads to remission of PAP symptoms. In these cases the disease is understood to be of a haematoremains unclear. A deficit in the production of GM-CSF has not yet been demonstrated in the cellular clones of poietic nature. In other cases, such as in congenital SP-B deficiency, where the pathogenic role of GM-CSF has still CML, and nor has a defect in the expression of the cytokine receptor. The (9,22) translocation does not affect the chronot been established, appropriateness of a hematopoietic transplant is questionable. mosome where the gene encoding GM-CSF is found. On the other hand, some information suggests that the Phϩ Alternatives such as therapy with GM-CSF have been referred to in the literature, suggesting that GM-CSF ALL cells may produce GM-CSF and express GM-CSF receptors showing a proliferative response to this cytoadministration activates AM and increases the rate of surfactant clearance.
14 kine. 20 Although the diagnosis of PAP in this patient was conHaematopoietic transplantation could play a substantial role in the cure of those cases of human PAP which are firmed by means of pulmonary biopsy by thoracotomy. BAL already suggested the disease. This case emphasises related to defects in the expression of a haematopoietic cytokine receptor. that a diagnosis of PAP should be considered in patients with haematological diseases and respiratory symptomatology. It also confirms the diagnostic value of standardising the use of BAL in these patients, as already proposed References by Cordonnier et al. 8 The reversibility of PAP occurring secondary to haema- 
